West Pharmaceutical Services (WST) Stock Forecast & Price Target

$331.40 +4.39 (+1.34%)

(As of 12/20/2024 05:17 PM ET)

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
1

Buy
4

Based on 5 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for WST.

Consensus Price Target

$437.75
32.09% Upside

According to the 5 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $437.75. The highest price target for WST is $536.00, while the lowest price target for WST is $355.00. The average price target represents a forecasted upside of 32.09% from the current price of $331.40.

Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

WST Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$437.75	$460.33	$442.75	$381.25
Forecasted Upside	32.09% Upside	45.40% Upside	44.35% Upside	7.42% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

West Pharmaceutical Services Stock vs. The Competition

Type	West Pharmaceutical Services	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	32.09% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent WST News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Bank of America 3 of 5 stars		Boost Target	Buy ➝ Buy	$350.00 ➝ $355.00	+8.95%
12/13/2024	Wolfe Research 3 of 5 stars	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
12/12/2024	UBS Group 4 of 5 stars	J. Sourbeer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$350.00 ➝ $390.00	+22.63%
2/13/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$440.00 ➝ $470.00	+15.58%
2/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$323.00 ➝ $536.00	+34.58%
10/27/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$420.00 ➝ $390.00	+20.06%
2/22/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$250.00 ➝ $290.00	-5.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:54 AM ET.

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

Recent stock performance shows an increase, with shares trading at approximately $325.68, indicating positive market sentiment and potential for further growth.
Institutional ownership is high at 93.90%, suggesting strong confidence from large investors, which can be a positive indicator for retail investors.
Significant recent acquisitions by institutional investors, such as FMR LLC increasing its stake by 199.4%, reflect growing interest and confidence in the company's future prospects.
The company has a solid market capitalization of $23.42 billion, which provides stability and resources for growth initiatives and innovation in the medical instruments sector.
West Pharmaceutical Services, Inc. has demonstrated resilience with a PE ratio of 47.97, indicating that investors are willing to pay a premium for its earnings, often a sign of expected growth.

West Pharmaceutical Services
Bear Case

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

Citigroup Inc. recently reduced its holdings by 32.0%, which may signal a lack of confidence in the stock's short-term performance.
The stock has a high PE ratio of 47.97, which could indicate that it is overvalued compared to its earnings, posing a risk if earnings do not meet investor expectations.
Insider selling activity, such as the recent sale of 703 shares by VP Charles Witherspoon, may raise concerns about the company's internal outlook and future performance.
Despite recent growth, the stock has a 1-year high of $413.70, suggesting that it may be approaching a peak, which could limit future upside potential.
Market volatility and economic uncertainties could impact the performance of West Pharmaceutical Services, Inc., especially in the healthcare sector, which is sensitive to regulatory changes and market conditions.

WST Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $437.75, with a high forecast of $536.00 and a low forecast of $355.00.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" WST shares.
: According to analysts, West Pharmaceutical Services's stock has a predicted upside of 32.09% based on their 12-month stock forecasts.
: Over the previous 90 days, West Pharmaceutical Services's stock had 1 upgrade by analysts.
: West Pharmaceutical Services has been rated by research analysts at Bank of America, UBS Group, and Wolfe Research in the past 90 days.
: Analysts like West Pharmaceutical Services less than other "medical" companies. The consensus rating score for West Pharmaceutical Services is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how WST compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Crypto Is Set to Explode in December (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

This page (NYSE:WST) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

West Pharmaceutical Services (WST) Stock Forecast & Price Target